Sekhmet Pharmaventures and the Nirma group are reportedly competing to buy Glenmark Life Sciences
Sekhmet Pharmaventures and the Nirma group are reportedly competing to buy the subsidiary. Glenmark owns 82.85 percent of GLS; Image: Shutterstock